Publicaciones (67) Publicaciones de ANDER URRUTICOECHEA RIBATE

2024

  1. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer

    Breast Cancer Research, Vol. 26, Núm. 1

  2. A randomized controlled trial of the effectiveness of a one-to-one peer support intervention on resilience, social support, and salivary cortisol in recently diagnosed women with breast cancer

    European Journal of Oncology Nursing, Vol. 71

  3. Acetyl-CoA carboxylase 1 controls a lipid droplet–peroxisome axis and is a vulnerability of endocrine-resistant eR+ breast cancer

    Science Translational Medicine, Vol. 16, Núm. 736

  4. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

  5. Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial

    Nature Medicine

2023

  1. A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma

    British Journal of Cancer, Vol. 129, Núm. 5, pp. 811-818

  2. Early Detection of Brain Metastases in a Supervised Exercise Program for Patients with Advanced Breast Cancer: A Case Report

    Medicine and science in sports and exercise, Vol. 55, Núm. 10, pp. 1745-1749

  3. Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2561-2570

2022

  1. Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study

    Trials, Vol. 23, Núm. 1

  2. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

    The Journal of clinical investigation, Vol. 132, Núm. 19

  3. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

    Journal of Clinical Investigation, Vol. 132, Núm. 7

2021

  1. Discovery and proof-of-concept study of nuclease activity as a novel biomarker for breast cancer tumors

    Cancers, Vol. 13, Núm. 2, pp. 1-16

  2. Omega 6 polyunsaturated fatty acids in red blood cell membrane are associated with xerostomia and taste loss in patients with breast cancer

    Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 173

2020

  1. Altered levels of desaturation and ω-6 fatty acids in breast cancer patients’ red blood cell membranes

    Metabolites, Vol. 10, Núm. 11, pp. 1-13

  2. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis

    Breast Cancer Research and Treatment, Vol. 180, Núm. 3, pp. 597-609

  3. Preliminary Qualitative and Quantitative Evaluation of DESIREE, a Decision Support Platform for the Management of Primary Breast Cancer Patients

    AMIA ... Annual Symposium proceedings. AMIA Symposium, Vol. 2020, pp. 1012-1021

  4. The urinary transcriptome as a source of biomarkers for prostate cancer

    Cancers, Vol. 12, Núm. 2

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

    Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108

  3. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

    Breast Cancer Research and Treatment, Vol. 174, Núm. 3, pp. 693-701